Development and validation of a nomogram to predict survival for advanced male breast cancer
Male breast cancer is a rare disease. Many experiences of male breast cancer were derived of female breast cancer. However, there are huge differences between two groups. We conducted this study to find a reliable prognostic model for advanced male breast cancer. The cohort was selected from the Sur...
Gespeichert in:
Veröffentlicht in: | Andrologia 2022-09, Vol.54 (8), p.e14479-n/a |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 8 |
container_start_page | e14479 |
container_title | Andrologia |
container_volume | 54 |
creator | Zhang, Li‐Ping Lin, Hui Wang, Ai‐Jing |
description | Male breast cancer is a rare disease. Many experiences of male breast cancer were derived of female breast cancer. However, there are huge differences between two groups. We conducted this study to find a reliable prognostic model for advanced male breast cancer. The cohort was selected from the Surveillance, Epidemiology, and End Results database. The enrolled patients were randomly divided into training and validation group. The univariate and multivariate analyses were used for prognostic assessment and a nomogram was built. Calibration curves and concordance index were compiled to determine predictive and discriminatory capacity. The time‐dependent receiver operating curves and the decision curve analysis was used to verify the model's ability. Two hundred and eighty individuals were enrolled. The cumulative rates of 1‐, 3‐ and 5‐year overall survival (OS) rates were 98.6%, 72% and 57.9%. The C‐indexes for OS were 0.835 (95%CI, 0.777–0.893) in the training group and 0.765 (95%CI, 0.668–0.862) in the validation group. The calibration curves confirmed the consistency of the nomogram both in the training and validation group. The time‐dependent receiver operating curves and decision curve analysis demonstrated that the nomogram had better prediction capacity than TNM stage system for advanced male breast cancer. The nomogram we built was a reliable and solid predictive model. |
doi_str_mv | 10.1111/and.14479 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2671264854</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2696933897</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3889-8f08154badd72637bad906bb942d496aca97ef741c5ae670c1001eca909a055e3</originalsourceid><addsrcrecordid>eNp10E1r3DAQBmBRUpol3UP_QBDkkh6cSNaXdVyyTVJY2kt7K5ixNA4OtrWR7A3776vNJjkUOpcRw8OLeAn5wtkVz3MNo7_iUhr7gSy4FLZgpSlPyIIJJgqptD0ly5QeWR6pjJHyEzkVSvPKKrsgf9a4wz5sBxwnmqPoDvrOw9SFkYaWAh3DEB4iDHQKdBvRd26iaY67LkPahkjB72B06OkAPdImIqSJusMpfiYfW-gTLl_3Gfl9--3XzX2x-Xn3_Wa1KZyoKltULau4kg14b0otTH5YppvGytJLq8GBNdgayZ0C1IY5zhjHfGUWmFIozsjlMXcbw9OMaaqHLjnsexgxzKkuteGllpWSmV78Qx_DHMf8u6ystkJU1mT19ahcDClFbOtt7AaI-5qz-tB6nauqX1rP9vw1cW4G9O_yreMMro_guetx__-kevVjfYz8C3fliu4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2696933897</pqid></control><display><type>article</type><title>Development and validation of a nomogram to predict survival for advanced male breast cancer</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zhang, Li‐Ping ; Lin, Hui ; Wang, Ai‐Jing</creator><creatorcontrib>Zhang, Li‐Ping ; Lin, Hui ; Wang, Ai‐Jing</creatorcontrib><description>Male breast cancer is a rare disease. Many experiences of male breast cancer were derived of female breast cancer. However, there are huge differences between two groups. We conducted this study to find a reliable prognostic model for advanced male breast cancer. The cohort was selected from the Surveillance, Epidemiology, and End Results database. The enrolled patients were randomly divided into training and validation group. The univariate and multivariate analyses were used for prognostic assessment and a nomogram was built. Calibration curves and concordance index were compiled to determine predictive and discriminatory capacity. The time‐dependent receiver operating curves and the decision curve analysis was used to verify the model's ability. Two hundred and eighty individuals were enrolled. The cumulative rates of 1‐, 3‐ and 5‐year overall survival (OS) rates were 98.6%, 72% and 57.9%. The C‐indexes for OS were 0.835 (95%CI, 0.777–0.893) in the training group and 0.765 (95%CI, 0.668–0.862) in the validation group. The calibration curves confirmed the consistency of the nomogram both in the training and validation group. The time‐dependent receiver operating curves and decision curve analysis demonstrated that the nomogram had better prediction capacity than TNM stage system for advanced male breast cancer. The nomogram we built was a reliable and solid predictive model.</description><identifier>ISSN: 0303-4569</identifier><identifier>EISSN: 1439-0272</identifier><identifier>DOI: 10.1111/and.14479</identifier><identifier>PMID: 35618959</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>advanced male breast cancer ; Breast cancer ; Epidemiology ; Mens health ; nomogram ; Nomograms ; Prediction models ; prognosis ; Rare diseases ; Survival</subject><ispartof>Andrologia, 2022-09, Vol.54 (8), p.e14479-n/a</ispartof><rights>2022 Wiley‐VCH GmbH.</rights><rights>2022 Wiley-VCH GmbH.</rights><rights>2022 Wiley‐VCH GmbH</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3889-8f08154badd72637bad906bb942d496aca97ef741c5ae670c1001eca909a055e3</citedby><cites>FETCH-LOGICAL-c3889-8f08154badd72637bad906bb942d496aca97ef741c5ae670c1001eca909a055e3</cites><orcidid>0000-0001-7198-6418</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fand.14479$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fand.14479$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35618959$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Li‐Ping</creatorcontrib><creatorcontrib>Lin, Hui</creatorcontrib><creatorcontrib>Wang, Ai‐Jing</creatorcontrib><title>Development and validation of a nomogram to predict survival for advanced male breast cancer</title><title>Andrologia</title><addtitle>Andrologia</addtitle><description>Male breast cancer is a rare disease. Many experiences of male breast cancer were derived of female breast cancer. However, there are huge differences between two groups. We conducted this study to find a reliable prognostic model for advanced male breast cancer. The cohort was selected from the Surveillance, Epidemiology, and End Results database. The enrolled patients were randomly divided into training and validation group. The univariate and multivariate analyses were used for prognostic assessment and a nomogram was built. Calibration curves and concordance index were compiled to determine predictive and discriminatory capacity. The time‐dependent receiver operating curves and the decision curve analysis was used to verify the model's ability. Two hundred and eighty individuals were enrolled. The cumulative rates of 1‐, 3‐ and 5‐year overall survival (OS) rates were 98.6%, 72% and 57.9%. The C‐indexes for OS were 0.835 (95%CI, 0.777–0.893) in the training group and 0.765 (95%CI, 0.668–0.862) in the validation group. The calibration curves confirmed the consistency of the nomogram both in the training and validation group. The time‐dependent receiver operating curves and decision curve analysis demonstrated that the nomogram had better prediction capacity than TNM stage system for advanced male breast cancer. The nomogram we built was a reliable and solid predictive model.</description><subject>advanced male breast cancer</subject><subject>Breast cancer</subject><subject>Epidemiology</subject><subject>Mens health</subject><subject>nomogram</subject><subject>Nomograms</subject><subject>Prediction models</subject><subject>prognosis</subject><subject>Rare diseases</subject><subject>Survival</subject><issn>0303-4569</issn><issn>1439-0272</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp10E1r3DAQBmBRUpol3UP_QBDkkh6cSNaXdVyyTVJY2kt7K5ixNA4OtrWR7A3776vNJjkUOpcRw8OLeAn5wtkVz3MNo7_iUhr7gSy4FLZgpSlPyIIJJgqptD0ly5QeWR6pjJHyEzkVSvPKKrsgf9a4wz5sBxwnmqPoDvrOw9SFkYaWAh3DEB4iDHQKdBvRd26iaY67LkPahkjB72B06OkAPdImIqSJusMpfiYfW-gTLl_3Gfl9--3XzX2x-Xn3_Wa1KZyoKltULau4kg14b0otTH5YppvGytJLq8GBNdgayZ0C1IY5zhjHfGUWmFIozsjlMXcbw9OMaaqHLjnsexgxzKkuteGllpWSmV78Qx_DHMf8u6ystkJU1mT19ahcDClFbOtt7AaI-5qz-tB6nauqX1rP9vw1cW4G9O_yreMMro_guetx__-kevVjfYz8C3fliu4</recordid><startdate>202209</startdate><enddate>202209</enddate><creator>Zhang, Li‐Ping</creator><creator>Lin, Hui</creator><creator>Wang, Ai‐Jing</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7198-6418</orcidid></search><sort><creationdate>202209</creationdate><title>Development and validation of a nomogram to predict survival for advanced male breast cancer</title><author>Zhang, Li‐Ping ; Lin, Hui ; Wang, Ai‐Jing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3889-8f08154badd72637bad906bb942d496aca97ef741c5ae670c1001eca909a055e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>advanced male breast cancer</topic><topic>Breast cancer</topic><topic>Epidemiology</topic><topic>Mens health</topic><topic>nomogram</topic><topic>Nomograms</topic><topic>Prediction models</topic><topic>prognosis</topic><topic>Rare diseases</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Li‐Ping</creatorcontrib><creatorcontrib>Lin, Hui</creatorcontrib><creatorcontrib>Wang, Ai‐Jing</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Andrologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Li‐Ping</au><au>Lin, Hui</au><au>Wang, Ai‐Jing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and validation of a nomogram to predict survival for advanced male breast cancer</atitle><jtitle>Andrologia</jtitle><addtitle>Andrologia</addtitle><date>2022-09</date><risdate>2022</risdate><volume>54</volume><issue>8</issue><spage>e14479</spage><epage>n/a</epage><pages>e14479-n/a</pages><issn>0303-4569</issn><eissn>1439-0272</eissn><abstract>Male breast cancer is a rare disease. Many experiences of male breast cancer were derived of female breast cancer. However, there are huge differences between two groups. We conducted this study to find a reliable prognostic model for advanced male breast cancer. The cohort was selected from the Surveillance, Epidemiology, and End Results database. The enrolled patients were randomly divided into training and validation group. The univariate and multivariate analyses were used for prognostic assessment and a nomogram was built. Calibration curves and concordance index were compiled to determine predictive and discriminatory capacity. The time‐dependent receiver operating curves and the decision curve analysis was used to verify the model's ability. Two hundred and eighty individuals were enrolled. The cumulative rates of 1‐, 3‐ and 5‐year overall survival (OS) rates were 98.6%, 72% and 57.9%. The C‐indexes for OS were 0.835 (95%CI, 0.777–0.893) in the training group and 0.765 (95%CI, 0.668–0.862) in the validation group. The calibration curves confirmed the consistency of the nomogram both in the training and validation group. The time‐dependent receiver operating curves and decision curve analysis demonstrated that the nomogram had better prediction capacity than TNM stage system for advanced male breast cancer. The nomogram we built was a reliable and solid predictive model.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35618959</pmid><doi>10.1111/and.14479</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-7198-6418</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0303-4569 |
ispartof | Andrologia, 2022-09, Vol.54 (8), p.e14479-n/a |
issn | 0303-4569 1439-0272 |
language | eng |
recordid | cdi_proquest_miscellaneous_2671264854 |
source | Wiley Online Library Journals Frontfile Complete |
subjects | advanced male breast cancer Breast cancer Epidemiology Mens health nomogram Nomograms Prediction models prognosis Rare diseases Survival |
title | Development and validation of a nomogram to predict survival for advanced male breast cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T08%3A59%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20validation%20of%20a%20nomogram%20to%20predict%20survival%20for%20advanced%20male%20breast%20cancer&rft.jtitle=Andrologia&rft.au=Zhang,%20Li%E2%80%90Ping&rft.date=2022-09&rft.volume=54&rft.issue=8&rft.spage=e14479&rft.epage=n/a&rft.pages=e14479-n/a&rft.issn=0303-4569&rft.eissn=1439-0272&rft_id=info:doi/10.1111/and.14479&rft_dat=%3Cproquest_cross%3E2696933897%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2696933897&rft_id=info:pmid/35618959&rfr_iscdi=true |